Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Design Therapeutics, Inc. - Common Stock
(NQ:
DSGN
)
12.73
-0.05 (-0.39%)
Streaming Delayed Price
Updated: 1:26 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Design Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
March 09, 2026
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in Upcoming Investor Conferences
February 18, 2026
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in Upcoming Investor Conferences
November 26, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Appoints Justin Gover to Board of Directors
September 10, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
August 27, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
August 07, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
June 04, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
May 28, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
May 13, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
May 07, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
May 01, 2025
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
April 21, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
April 17, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
April 17, 2025
From
Bright Peak Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
March 10, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
March 03, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
November 13, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
November 07, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
August 05, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
May 08, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
March 12, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
November 13, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
August 14, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
August 14, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
May 31, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
May 09, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
